Pilot study of the use of Janus Kinase Inhibitor, Baricitinib, in the treatment of heritable interferonopathy Aicardi Goutières Syndrome (P3.323)
Adeline Vanderver(Children's Hospital of Philadelphia), Amy Waldman(Children's Hospital of Philadelphia), Asako Takanohashi(Children's Hospital of Philadelphia), Deborah Foerster, Jamie Koh(Children's Hospital of Philadelphia), Sarah Woidill(Children's Hospital of Philadelphia), Raphaela Goldbach‐Mansky(National Institutes of Health), Nicole Ulrick(Children's Hospital of Philadelphia), Francesco Gavazzi(Children's Hospital of Philadelphia), Jullie Rhee(Children's National), Justine Shults(Children's Hospital of Philadelphia), Thaís Armangué(Universitat de Barcelona), Laura Adang(Children's Hospital of Philadelphia)
Cited by 2
Related Papers
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study
|The Lancet Neurology|2013|3.1k
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
|New England Journal of Medicine|2006|902
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models
|The Lancet Neurology|2019|853